Past studies have found that high consumption of grilled, barbecued, or smoked meats increases one’s risk of developing breast cancer, but according to the new study by University of North Carolina at Chapel Hill, “High intake of grilled/barbecued and smoked meat may increase mortality after breast cancer.”
Although some studies have linked the personal use of hair dyes with increased risks of certain cancers of the blood and bone marrow, such as non-Hodgkin lymphoma (NHL) and leukemia, other studies have not shown such links. Studies of breast and bladder cancer have also produced conflicting results. Relatively few studies have been published about the association of hair dye use with the risk of other cancers. Based on its review of the evidence, the IARC Working Group concluded that personal use of hair dyes is “not classifiable as to its carcinogenicity to humans”
After undergoing treatment for early-stage breast cancer, many postmenopausal women take drugs known as aromatase inhibitors to reduce the risk of the cancer returning. These drugs, however, can cause significant pain in women’s joints and muscles. The clinical trialExit Disclaimer showed that duloxetine (Cymbalta®), which is approved to treat depression and anxiety as well as fibromyalgia and nerve pain caused by diabetes, provided some relief from pain associated with aromatase inhibitors.
Although we should avoid sugar, artificial sugar substitutes containing aspartame, saccharin or sucralose have been shown to contribute to bladder cancer, lymphoma and leukemia, according to the National Institute of Environmental Health Sciences. Good sugar substitutes are stevia (an all-natural herb from South America), barley malt, rice syrup, and palm sugar. Even high-glycemic sweeteners like Sucanat, evaporated cane juice, molasses, honey and pure maple syrup are nutritionally superior to refined table sugar or HFCS, and you can avoid sugar spiking if you consume them in the presence of high fiber foods like ground flaxseeds.
“Personally, it’s hard to articulate how much I get from this. The process is complicated and it requires trust and vulnerability on both sides but to be able to use your talent and craft to help someone is an honor. There is healing in this.”
Is that a lump I can feel? Should I be worried about the dimpled skin there? What exactly am I feeling for? Those were the concerns of Corrine Beaumont, a young designer, who created the ‘Know Your Lemons’ campaign, which has been shared more than 32,000 times on Facebook in the past few days.
As immunotherapy research takes off, the patients getting the treatment have been overwhelmingly white. Researchers know this and say they are trying to correct it.
One in three women with breast cancer detected by a mammogram is treated unnecessarily, because screening tests found tumors that are so slow-growing that they’re essentially harmless, according to a Danish study published Monday in Annals of Internal Medicine, which has renewed debate over the value of early detection.
The evidence is overwhelming that the primary cause of cancer is toxins in the environment, which means that it’s preventable. Yet the National Cancer Institute refuses to acknowledge toxins as a major cause. It consistently understated the connection, maintaining that only 6% of all cancer cases stem from environmental and occupational carcinogens.
“Our study, from one of the largest nationwide studies to date, shows that cancer-related cognitive problems are a substantial and pervasive issue for many women with breast cancer,” Janelsins-Benton, an assistant professor of surgery, said in a press release. “We are currently assessing these data in the context of objective cognitive measures and to understand the role of possible biologic mechanisms that may confer risk to cognitive problems in patients.”
Biocept’s Target Selector platform is designed to detect biomarkers of tumor cells originating from breast cancer in CSF samples. If proven effective, it could help doctors diagnose brain metastases in women with breast cancer and initiate treatment.
Minimally Invasive Breast Cancer Cryotherapy Largely Ignored in U.S., Says Advocate and 13-Year Survivor
Laura Ross-Paul of Portland, Oregon, calls herself a “patient pioneer,” as one of the first women in the world to receive cryoablation as the primary treatment for her multi-focused breast cancer 13 years ago.“The beauty of cryoablation,” Ross-Paul said, “is that it is breast conserving — I was able to avoid a mastectomy,” its low morbidity — “I never needed more than a Tylenol,” and its inexpensive cost compared to surgery. Ross-Paul says another major benefit of cryoablation is that in about half of all cases, “cryoablation naturally stimulates the body’s immune system to develop an immunity to the cancer as it eats up the now-dead tumors.”
Women with stronger social networks while receiving treatment for breast cancer were found to have better outcomes than those without a support system, recent evidence suggests.
Oxygen deprivation can activate a cell mechanism that prompts triple-negative breast cancer cells to migrate to other parts of the body, a finding that could lead to better treatments, a study says.
In just under four years, researchers have identified the gene involved in the development of metaplastic breast cancer — the most aggressive type of triple-negative breast cancer — and advanced a potential treatment for the disease to clinical trials. “The results showed elimination of the cancer in nearly all of the mice when combined with standard chemotherapy,” said Chang, who is also a professor of medicine at Weill Cornell Medicine. “Our goal is to turn metaplastic breast cancer from a debilitating disease into a chronic illness.
A new cancer vaccine that uses a patient’s own immune-regulating dendritic cells to target the HER2 protein can activate the immune system and cause regression of early-stage HER2-positive breast cancer, according to a study. The therapy is particularly effective in patients with a non-invasive form of the disease called ductal carcinoma in situ (DCIS), as compared with patients with an early-stage invasive disease, researchers said.
If you want to be a patient who can take charge of her own treatment, you need to have a basic understanding of how cancer research works, so you can use it to make decisions about your care.
Researchers have identified two new factors that may help to determine whether a patient with estrogen receptor-positive breast cancer will respond to treatment. In addition to preventing the estrogen receptor from being degraded — and impairing drugs that target it from combating the cancer — a lack of the enzymes LATS1 and LATS2 makes cancer development much more likely, according to “The Hippo kinases LATS1 and 2 control human breast cell fate via crosstalk with ERα.” The study was published in the journal Nature.
The FDA and Congress should develop tougher requirements for proving cosmetic chemicals are safe before coming to market. All too often, products are on the market for years before scientists catch up with possible hazards in their formulations. Once hazards are suspected, the FDA moves at a snail’s pace in regulating potentially harmful ingredients. Responsible manufacturers can voluntarily remove these ingredients and we hope they will. Ultimately, it’s up to consumers to read labels, vote with their pocketbooks and force the market to change for the better.
Adapted Media Release
Study finds substantial rate of contralateral prophylactic mastectomy when procedure not indicated
Published: Monday 2 January 2017
In a survey of women who underwent treatment for early-stage breast cancer in one breast, contralateral prophylactic mastectomy (CPM; both breasts are surgically removed, the breast that contains cancer and the healthy breast) use was substantial among patients without clinical indications but was low when patients reported that their surgeon recommended against it, according to a study published online by JAMA Surgery. Many patients considered CPM, but knowledge about the procedure was low and discussions with surgeons appeared to be incomplete.